{
    "clinical_study": {
        "@rank": "40224", 
        "acronym": "ESTHER-2", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "FE 999049"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Active Comparator", 
                "description": "Follitropin alfa (Gonal-F)"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial investigates the immunogenicity of FE 999049 in repeated cycles."
        }, 
        "brief_title": "Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Infertility", 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed Consent Documents signed prior to screening evaluations related to this\n             protocol\n\n          -  Participation in the pivotal efficacy trial (trial 000004/ESTHER-1)\n\n          -  Anti-FSH antibody results from baseline and at least one post-dosing assessment in\n             the previous cycle(s) available.\n\n          -  Having undergone the oocyte retrieval procedure, or having had cycle cancellation\n             prior to oocyte retrieval due to poor ovarian response or excessive ovarian response,\n             in the previous cycle(s).\n\n          -  Failure to achieve ongoing pregnancy in the previous cycle(s).\n\n        Exclusion Criteria:\n\n          -  Non-compliance to protocol compliance in the previous cycle(s).\n\n          -  Having undergone any stimulation with gonadotropins since the end-of-trial /\n             end-of-cycle visit in the previous cycle\n\n          -  One or more follicles \u226510 mm observed on the transvaginal ultrasound prior to start\n             of dosing on stimulation day 1\n\n          -  Severe OHSS in a previous cycle.\n\n          -  Any clinically relevant change to any of the eligibility criteria in the previous\n             cycle(s).\n\n          -  Clinically relevant medical history since the previous cycle which precludes\n             gonadotropin stimulation or is associated with a reduced chance of pregnancy."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01956123", 
            "org_study_id": "000071", 
            "secondary_id": [
                "2013-001616-30", 
                "U1111-1147-6922"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "A", 
                "intervention_name": "FE 999049", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B", 
                "intervention_name": "Follitropin alfa (Gonal-F)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Follicle Stimulating Hormone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium"
                    }, 
                    "name": "UZ Brussel (there may be other sites in this country)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegro, Rio Grande Do Sul", 
                        "country": "Brazil"
                    }, 
                    "name": "Fertilitat and PUC-RS (there may be other sites in this country)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burnaby", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }, 
                    "name": "Pacific Centre for Reproductive Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }, 
                    "name": "Olive Fertility Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Ottawa Fertility Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic"
                    }, 
                    "name": "IVF CUBE SE (there may be other sites in this country)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark"
                    }, 
                    "name": "Rigshospitalet Fertilitetsklinikken (there may be other sites in this country)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France"
                    }, 
                    "name": "Department of Endocrine Gynaecology and Reproductive Medicine, H\u00f4pital Jeanne de Flandre (there may be other sites in this country)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "Centro Natalit\u00e0 San Raffaele (there may be other sites in this country)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warszawa", 
                        "country": "Poland"
                    }, 
                    "name": "The nOvum Clinic (there may be other sites in this country)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "IVI Sevilla (there may be other sites in this country)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Glasgow Centre for Reproductive Medicine Ltd. (there may be other sites in this country)"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Brazil", 
                "Canada", 
                "Czech Republic", 
                "Denmark", 
                "France", 
                "Italy", 
                "Poland", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Controlled, Assessor-blind, Parallel Groups, Multicentre, Multinational Trial Evaluating the Immunogenicity of FE 999049 in Repeated Cycles of Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme", 
        "overall_official": {
            "affiliation": "Ferring Pharmaceuticals", 
            "last_name": "Clinical Development Support", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Belgium: Ethics Committee", 
                "Czech Republic: Ethics Committee", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: Ethics Committee", 
                "Denmark: Danish Medicines Agency", 
                "France: Committee for the Protection of Personnes", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Poland: Ethics Committee", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Spain: Ethics Committee", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "United Kingdom: Research Ethics Committee", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Proportion of subjects with treatment-induced anti-FSH antibodies after up to two repeated controlled ovarian stimulation cycles", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 28 days after end of the last stimulation period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01956123"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of subjects with treatment-induced anti-FSH antibodies with neutralising capacity after up to two repeated controlled ovarian stimulation cycles", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days after end of the last stimulation period"
            }, 
            {
                "measure": "Proportion of subjects with treatment-induced anti-FSH antibodies, overall as well as with neutralising capacity, after one and after two repeated controlled ovarian stimulation cycles", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days after end of the last stimulation period"
            }, 
            {
                "measure": "Proportion of subject with cycle cancellation due to poor ovarian response or excessive ovarian response for each controlled ovarian stimulation cycle", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 20 stimulation days"
            }, 
            {
                "measure": "Vital pregnancy rate for each controlled ovarian stimulation cycle", 
                "safety_issue": "No", 
                "time_frame": "5-6 weeks after blastocyst transfer"
            }, 
            {
                "measure": "Implantation rate for each controlled ovarian stimulation cycle", 
                "safety_issue": "No", 
                "time_frame": "5-6 weeks after blastocyst transfer"
            }, 
            {
                "measure": "Ongoing pregnancy rate for each controlled ovarian stimulation cycle", 
                "safety_issue": "No", 
                "time_frame": "10-11 weeks after blastocyst transfer"
            }, 
            {
                "measure": "Ongoing implantation rate for each controlled ovarian stimulation cycle", 
                "safety_issue": "No", 
                "time_frame": "10-11 weeks after blastocyst transfer"
            }, 
            {
                "measure": "Frequency of injection site reactions (redness, pain, itching, swelling and bruising) assessed by the subject during the stimulation period for each controlled ovarian stimulation cycle", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 20 stimulation days"
            }, 
            {
                "measure": "Proportion of subjects with late OHSS (including OHSS of moderate/severe grade) for each controlled ovarian stimulation cycle", 
                "safety_issue": "Yes", 
                "time_frame": ">9 days after triggering of final follicular maturation"
            }, 
            {
                "measure": "Technical malfunctions of the administration pen for each controlled ovarian stimulation cycle", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 20 stimulation days"
            }
        ], 
        "source": "Ferring Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}